Announcement PDF ASX Announcement 02/03/2021 Emyria adds second clinic in Perth ahead of EMD-003 registration trials Highlights: ● Emyria has added a second suite of Emerald Clinics consulting rooms in Perth on the back of continued appointment growth nationally ● Potential to double capacity of Perth and builds on recent expansion in Melbourne ● The new clinic is co-located with site of West Leederville Private Hospital ● Additional clinical rooms will also help support the pivotal clinical trials, currently in planning, in support of the registration of EMD-003 Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development company, is pleased to announce the expansion of its clinical service subsidiary - Emerald Clinics - with the addition of a second consulting suite in Perth. The expansion comes off the back of record patient appointments in January 2021 and a recently announced expansion in Victoria. (See ASX release 09 Feb 21) Meeting growing patient demand and adding capacity for trials The new Perth suite has capacity for 4 additional consulting rooms and is co-located within the site of West Leederville Private Hospital complex. The Perth expansion will boost clinical capacity in WA and support Emyria to: ● Improve patient access to Emerald Clinics services ● Conduct pivotal clinical trials currently being planned for Emyria’s first drug development program, EMD-003, targeting unmet needs in mental health and seeking registration as a Schedule 3 medicine. (See ASX release 05 Jan 21) ● Deliver on a recently awarded grant from the WA Government. The grant award of $880,000 was won with research partner, the University of Western Australia. Emyria’s technology and team will play a lead role monitoring the clinical and mental health of vulnerable patients remotely (see ASX release 05 Feb 21) West Leederville site Emyria’s Managing Director, Dr Michael Winlo, said: “Western Australia was the first Emerald Clinics location. Demand for our services from both patients and referring doctors has grown every month since we opened. We anticipate this expansion will allow us to improve our waiting times and see more patients which, in turn, improves our proprietary data asset (Emyria Data). 1 Insights from Emyria Data is now informing the design and planning of pivotal drug registration clinical trials for our first drug program, EMD-003 - a cannabinoid medicine targeting unmet needs in mental health. The additional clinical capacity in Perth also allows us to support a wider range of clinical trials in different indications as well as help us deliver on the recently awarded Future Health Research and Innovation Grant involving our TGA-registered remote monitoring system.” The second Perth Emerald Clinics location is at - 2 McCourt Street, West Leederville. This announcement has been approved and authorised for release by the Managing Director of Emyria Limited. For further information: Dr Michael Winlo Managing Director (08) 6559 2800 mwinlo@emyria.com Lexi O’Halloran Media/Investor Relations + 61 (0) 404 577 076 lexi@janemorganmanagement.com.au Andrew Williams Media Relations +61 (0) 412 614 125 andreww@profilemedia.com.au About Emyria (www.emyria.com) Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services (Emerald Clinics - www.emeraldclinics.com.au) Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. 2